| 223.51 Delayed Data As of Oct 21 |  +3.45 / +1.57%Today’s Change | 215.78 Today|||52-Week Range 344.00 | -25.72% Year-to-Date |
| Why Did the Market Whack This IPO? Oct 14 / MotleyFool.com - Paid Partner Content | Better Buy: Biogen vs. Gilead Sciences Oct 10 / MotleyFool.com - Paid Partner Content |
| Previous close | 220.06 |
| Today’s open | 222.00 |
| Day’s range | 221.56 - 225.78 |
| Volume | 2,429,054 |
| Average volume (3 months) | 1,556,955 |
| Market cap | $40.6B |
| Earnings growth (last year) | +81.10% |
| Earnings growth (this year) | +23.34% |
| Earnings growth (next 5 years) | +2.84% |
| Revenue growth (last year) | +9.67% |
| P/E ratio | 8.3 |
| Price/Sales | 5.13 |
| Price/Book | 3.33 |
| Today’s change | Today’s % change | |
|---|---|---|
| ILMNIllumina Inc | +4.39 | +1.42% |
| EXASExact Sciences Corp | -3.68 | -3.81% |
| BMRNBiomarin Pharmaceuti... | -0.73 | -1.06% |
| NBIXNeurocrine Bioscienc... | +1.49 | +1.56% |
| Last reporting date | October 22, 2019 |
| EPS forecast (this quarter) | $8.28 |
| Annual revenue (last year) | $12.1B |
| Annual profit (last year) | $4.4B |
| Net profit margin | 36.76% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
